Key result
Recent advances in antithrombotic therapy for acute coronary syndromes have focused on developing novel agents with more predictable efficacy, increased target specificity, and reduced variation.
The contemporary therapeutic armory for ACS reflects pharmacological advances aimed at improving efficacy and minimizing complications through increased target specificity.
Highlights evolving antithrombotic options for ACS; leaves open which agents will prove superior in trials.
Anti-thrombotic drugs constitute the cornerstone of therapy in the management of acute coronary syndromes (ACS) and for patients undergoing percutaneous coronary intervention. Anti-thrombotic therapy during percutaneous coronary intervention for ACS has evolved substantially over the past 15 years. In the original 1996 ACC/AHA guidelines for the management of acute myocardial infarction (MI), only one antiplatelet agent (aspirin) and one anticoagulant (unfractionated heparin) were recommended as class I therapies. Much has since changed and the contemporary therapeutic armoury for the treatment of ACS reflects the pharmacological advances that have taken place. Recent developments in the medical management of ACS have been based around developing drugs with more predictable efficacy and at known drug targets. However there has also been considerable development of novel agents. New pharmacotherapies for ACS reflect efforts to improve efficacy and minimize complications by increasing target specificity and reducing inter-individual variation in therapeutic response.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2014) conducted a review in Acute coronary syndromes. Anti-thrombotic drugs was evaluated. Recent advances in antithrombotic therapy for acute coronary syndromes have focused on developing novel agents with more predictable efficacy, increased target specificity, and reduced variation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: